Attending this event?
Back To Schedule
Monday, September 19 • 11:00am - 11:45am
Panel: The R&D Dilemma: Embracing New Modalities vs. Tried-and-True Approaches

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

The last few decades have seen the biotech industry lead the charge in R&D innovation. But as companies look for ways to differentiate their products, R&D efforts have shifted from small molecules to exploring more advanced therapies. Is this the right approach for every company? Developing a molecule that doesn’t progress as hoped can be make or break for a biotech and have a drastic impact on their ability to raise capital or find partners.  
This session will explore the pros and cons of sticking to an area of research that is tried and tested vs. embracing new modalities of treatment, and how to navigate the unique challenges of emerging modalities such as the ability to manufacture these treatments.

avatar for Michelle Benz

Michelle Benz

Senior Conference Producer, Questex - Fierce Life Sciences

avatar for Mike Ellis, PhD

Mike Ellis, PhD

Senior Vice President of Small Molecule Drug Discovery, Bristol Myers Squibb
Mike Ellis, PhD, serves as the senior vice president of Small Molecule Drug Discovery (SMDD). Mike and the SMDD team partner with cross-functional scientists throughout Bristol Myers Squibb’s network of thematic research centers to create and advance potentially transformational... Read More →
avatar for Iris Grossman, PhD

Iris Grossman, PhD

Chief Therapeutics Officer, Eleven Therapeutics
On the leading edge of Personalized Medicine & Data Analytics ~20 yearsWorked for or consulted for 4 of the top Big PharmaLed, as CSO, platform-driven start-ups into therapeutic entities with broad pipelines & capabilities, including a multi-year multi-million Dollar partnershipChampioned... Read More →
avatar for Charles Lin Ph.D.

Charles Lin Ph.D.

Sr. Vice President, Biology, Kronos Bio, Inc.

Monday September 19, 2022 11:00am - 11:45am EDT